Vivoryon Therapeutics NV
VVY.EU
$0.61
Closing
▲25.83%
1D
▼-93.00%
YTD
Market cap
$15.83M
52 week high
$20.84
52 week low
$0.44
Volume
546,850
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$15.83M
Analysts' Rating
BUY
Price Target (Mean)
41.54324801
Total Analysts
1
P/E
Operating Margin
0.00%
Beta
1.50
Revenue Growth (Annual)
-100.00%
52 week high
$20.84
52 week low
$0.44
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.
